Insights

Gathering insights about LACE…

Similar companies to LACE

LACE Tech Stack

LACE uses 8 technology products and services including Google Font API, jQuery, SweetAlert, and more. Explore LACE's tech stack below.

Google Font API
Font Scripts
jQuery
Javascript Libraries
SweetAlert
Javascript Libraries
OWL Carousel
Javascript Libraries
PHP
Programming Languages
reCAPTCHA
Security
Google Tag Manager
Tag Management
Bootstrap
UI Frameworks

Media & News

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it is in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company's cash, including a potential transaction with investor David Lazar of Activist Investing, LLC, which transaction would be subject to the consent of an existing securityholder.
Dec 05, 2024 | www.globenewswire.com
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
BERKELEY HEIGHTS, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it closed its previously announced transaction involving the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issued upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-279157).
Nov 14, 2024 | www.globenewswire.com
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
BERKELEY HEIGHTS, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-279157).
Nov 13, 2024 | www.globenewswire.com
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced third quarter financial results and provided a business update.
Nov 12, 2024 | www.globenewswire.com
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
BERKELEY HEIGHTS, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an extension until December 24, 2024, to regain compliance with Nasdaq's minimum stockholders equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard Rule").
Oct 24, 2024 | www.globenewswire.com
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
NEW CLINICAL DATA FROM ONGOING, PHASE 2 STUDY OF ORAL FADRACICLIB AT THE 2024 ENA SYMPOSIUM. Patients preselected for CDKN2A and/or CDKN2B abnormalities
Oct 23, 2024 | www.globenewswire.com
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities
Oct 09, 2024 | www.globenewswire.com

LACE's Email Address Formats

LACE uses at least 1 format(s):

LACE Email Formats	Example	Percentage
First.Last@laceeng.com.br	John.Doe@laceeng.com.br	31%
First@laceeng.com.br	John@laceeng.com.br	19%
First.Last@laceeng.com.br	John.Doe@laceeng.com.br	31%
First@laceeng.com.br	John@laceeng.com.br	19%

Frequently Asked Questions

Where is LACE's headquarters located?

LACE's main headquarters is located at Avenida Doutor Altino Bondensan, 500 - Distrito de Eugênio de Melo Parque Tecnológico - São José dos Campos - Centro Empresarial IV - Sala n. 1303 São José dos Campos, SP 12.247-016 BR. The company has employees across 6 continents, including South AmericaEuropeNorth America.

What is LACE's stock symbol?

LACE is a publicly traded company; the company's stock symbol is CYCCP.

What is LACE's official website and social media links?

LACE's official website is laceeng.com.br and has social profiles on LinkedIn.

What is LACE's NAICS code?

LACE's NAICS code is 335 - Electrical Equipment, Appliance, and Component Manufacturing.

How many employees does LACE have currently?

As of July 2021, LACE has approximately 48 employees across 6 continents, including South AmericaEuropeNorth America. Key team members include Chief Marketing Officer: L. S.Chief Financial Officer: L. I.Ceo: H. L. D. F.. Explore LACE's employee directory with LeadIQ.

What industry does LACE belong to?

LACE operates in the Appliances, Electrical, and Electronics Manufacturing industry.

What technology does LACE use?

LACE's tech stack includes Google Font APIjQuerySweetAlertOWL CarouselPHPreCAPTCHAGoogle Tag ManagerBootstrap.

What is LACE's email format?

LACE's email format typically follows the pattern of . Find more LACE email formats with LeadIQ.

When was LACE founded?

LACE was founded in 2015.

LACE

Appliances, Electrical, and Electronics ManufacturingSão Paulo, Brazil11-50 Employees

LACE is an electronic engineering company focused on electromagnetic (EMC) solutions to the industry. Products like lightning protection devices and services as advisory on certification for automotive electronic systems are a few examples of how we help our clients.

The company was founded in 2015 by professionals from the aeronautical and automotive industries with solid experience in development and certification projects regarding EMC & EMI. Our business model is lean, focused on solving problems for the customers. Our skilled team can deliver several EMC solutions, such as design & manufacturing, test & analysis, engineering consultancy and computer simulation.

Company Overview

Headquarters: Avenida Doutor Altino Bondensan, 500 - Distrito de Eugênio de Melo Parque Tecnológico - São José dos Campos - Centro Empresarial IV - Sala n. 1303 São José dos Campos, SP 12.247-016 BR
Website: laceeng.com.br
Stock Symbol: CYCCP
NAICS Code: 335 - Electrical Equipment, Appliance, and Component Manufacturing
Founded: 2015
Employees: 11-50

Media & News

Funding & Financials

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to LACE

Tenneco

Nordex SE

Arla Foods

Rakvere Lihakombinaat AS

Smurfit Kappa

AB VASSILOPOULOS

LACE Tech Stack

Media & News

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

LACE's Email Address Formats

Frequently Asked Questions

Where is LACE's headquarters located?

What is LACE's stock symbol?

What is LACE's official website and social media links?

What is LACE's NAICS code?

How many employees does LACE have currently?

What industry does LACE belong to?

What technology does LACE use?

What is LACE's email format?

When was LACE founded?

LACE

Company Overview

Media & News

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?